U.S. Capital Wealth Advisors LLC Raises Position in Pfizer Inc. (NYSE:PFE)

U.S. Capital Wealth Advisors LLC raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 33.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 399,972 shares of the biopharmaceutical company's stock after purchasing an additional 99,278 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Pfizer were worth $10,135,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of PFE. Raleigh Capital Management Inc. lifted its holdings in shares of Pfizer by 8.4% in the first quarter. Raleigh Capital Management Inc. now owns 63,008 shares of the biopharmaceutical company's stock valued at $1,597,000 after purchasing an additional 4,881 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Pfizer by 30.4% during the 1st quarter. TD Private Client Wealth LLC now owns 127,653 shares of the biopharmaceutical company's stock valued at $3,235,000 after acquiring an additional 29,754 shares during the last quarter. OLD Republic International Corp increased its holdings in shares of Pfizer by 0.6% during the 1st quarter. OLD Republic International Corp now owns 1,623,700 shares of the biopharmaceutical company's stock valued at $41,145,000 after acquiring an additional 9,000 shares during the last quarter. Capital Advisors Inc. OK increased its holdings in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after acquiring an additional 17,032 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in Pfizer by 13.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 10,402,113 shares of the biopharmaceutical company's stock valued at $263,590,000 after buying an additional 1,231,296 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on PFE. BMO Capital Markets lowered their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Jefferies Financial Group lifted their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Citigroup lifted their target price on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Redburn Atlantic decreased their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.53 during mid-day trading on Tuesday, hitting $25.77. 14,808,733 shares of the stock traded hands, compared to its average volume of 41,596,354. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a market cap of $146.53 billion, a PE ratio of 18.67, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The firm has a 50 day simple moving average of $23.76 and a two-hundred day simple moving average of $24.81.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the business earned $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.67%. Pfizer's payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.